Contribution of real-life studies in France during the COVID-19 pandemic and for the national pharmaco-epidemiological surveillance of COVID-19 vaccines

During the COVID-19 pandemic, EPI-PHARE, a scientific group in pharmaco-epidemiology created by the French National Agency for the Safety of Medicines and Health Products (ANSM) and the French National Health Insurance (Cnam), has reoriented its work program to enlighten health authorities in this h...

Descripción completa

Detalles Bibliográficos
Autores principales: Zureik, Mahmoud, Cuenot, François, Weill, Alain, Dray-Spira, Rosemary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Masson SAS on behalf of Société française de pharmacologie et de thérapeutique. 2023
Materias:
Pharmacoepidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851737/
https://www.ncbi.nlm.nih.gov/pubmed/36739224
http://dx.doi.org/10.1016/j.therap.2022.12.013
Descripción
Sumario:During the COVID-19 pandemic, EPI-PHARE, a scientific group in pharmaco-epidemiology created by the French National Agency for the Safety of Medicines and Health Products (ANSM) and the French National Health Insurance (Cnam), has reoriented its work program to enlighten health authorities in this health crisis. By exploiting massive and complex data of the French Health Data System (SNDS) from the beginning of the first lockdown in France in March 2020, we were able to publish numerous results on the use, benefits and risks of medicines, on the risk factors of COVID-19 before and after vaccination, and on the benefits and risks of COVID-19 vaccines. Our results were widely taken into account by the French health authorities and allowed them to take informed decision in this pandemic situation in order to ensure the health of the population.

Ejemplares similares